To the full analysis
Mesoblast stock: growth
MESOMesoblast reported $120.79M in revenue for fiscal 2026, up 602.3% on the prior year, up 74.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
25.2%
per year from 2007 to 2026, per share 19.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 74.5% | 11.0% | 25.2% |
| Revenue per share | 49.9% | 1.7% | 19.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $1.68M | −$8.73M | −$9.28M |
| 2008 | $909.81K | −$10.06M | −$6.3M |
| 2009 | $890.71K | −$12.29M | −$9.41M |
| 2010 | $5.5K | −$14.78M | −$9.74M |
| 2011 | $120.92M | $90.61M | $107.77M |
| 2012 | $38.28M | −$71.15M | −$74.82M |
| 2013 | $28.79M | −$61.66M | −$56.92M |
| 2014 | $25.98M | −$80.96M | −$119.78M |
| 2015 | $23.75M | −$119.37M | −$124.43M |
| 2016 | $42.55M | −$4.13M | −$88.92M |
| 2017 | $2.41M | −$76.82M | −$95.78M |
| 2018 | $17.34M | −$35.29M | −$75.21M |
| 2019 | $16.72M | −$89.8M | −$58.07M |
| 2020 | $32.16M | −$77.94M | −$58.61M |
| 2021 | $7.46M | −$98.81M | −$108.33M |
| 2022 | $10.21M | −$91.35M | −$66.01M |
| 2023 | $7.5M | −$81.89M | −$63.58M |
| 2024 | $5.9M | −$87.96M | −$48.79M |
| 2025 | $17.2M | −$102.14M | −$50.68M |
| 2026 | $120.79M | −$57.76M | −$44.73M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2012)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.